SFTPC, a marker of ATII cells, has been reported to inhibit epithelial-to-mesenchymal transition by upregulating SOX7 and inactivating the WNT/β-catenin pathway.53 Another study demonstrated that SFTPC expression is progressively downregulated during lung cancer progression and is completely absent in lung cancer tissues with brain metastases.54 Despite these findings, the molecular mechanisms underlying metastasis in LUAD require further investigation. The gene discussed is SFTPC; the disease is lung cancer.